Vivos Therapeutics Announces Formation of New Medical Consortium to Advance the Company’s Technology for Obstructive Sleep Apnea
Retrieved on:
Thursday, September 23, 2021
Anthony J. DeMaria, Therapy, Securities Act of 1933, Chairperson, Forensic pathology, Family medicine, Consultant, University, Program, Stanford University, Obstructive sleep apnea, SEC, Research, Science and technology in Asia, Drug Quality and Security Act, Sleep medicine, Medical director, Physician, Behavioural sciences, Adult, Sleep apnea, Awareness, Technology, Death, VIP, Dentist, Obstetrics, Pediatrics, Cardiology, OSA, Icahn School of Medicine at Mount Sinai, NASDAQ, U.S. Securities and Exchange Commission, University of Alberta, Company, Neurology, Tissue, Alberta, Apnea–hypopnea index, GLOBE, Department, Adoption, Sleep surgery, Assistant, DRS, Risk, Security (finance), Patient, Psychiatry, Securities Exchange Act of 1934, Quality of life, Snoring, Pharmaceutical industry, Dentistry, Medicine
(the Company or Vivos) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (OSA) and snoring, announced today the official formation of the Vivos Medical Consortium.
Key Points:
- (the Company or Vivos) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (OSA) and snoring, announced today the official formation of the Vivos Medical Consortium.
- For decades, the only treatment options for sleep apnea were limited and often invasive, but with the Vivos technology, that has changed dramatically.
- Commenting on the anticipated impact of the Vivos Medical Consortium, Vivos Chairman and CEO Kirk Huntsman stated, Obstructive sleep apnea is a serious medical problem, yet it is one that, through the use of the Vivos technology, now has a highly effective medical solution that can be delivered by a dentist.
- Vivos Therapeutics Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for adult patients suffering from sleep-disordered breathing, including obstructive sleep apnea (OSA).